source
- Novo files US and EU approval for etavopivat, its $1B acquired sickle-cell therapyNovo submitted regulatory applications in the United States and Europe for etavopivat, a sickle cell disease therapy it bought from Forma Therapeutics in a $1 billion transaction. The company says…
- Arrowhead faces challenges as Ionis's Tryngolza sales fall short, putting sHTG launch at riskIonis Pharmaceuticals reported flat sales of its severe hypertriglyceridemia drug Tryngolza, generating only $9 million and cutting its annual revenue outlook to $50 million. The weak performance…